Company Overview
Prestige Consumer Healthcare Inc. operates as a developer, manufacturer, marketer, distributor, and seller of over-the-counter (OTC) health and personal care products across North America, Australia, and international markets. The company functions within the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry, a classification that defines its focus on non-prescription therapeutic solutions for consumer use. Prestige Consumer Healthcare Inc. maintains a substantial operational scale with a market capitalization of $2.89B, an annual revenue of $1.10B, and an employee base of 600 individuals. These valuation and revenue figures indicate that the company holds a significant position within its niche, possessing the financial resources and operational footprint to compete effectively in the global OTC landscape while maintaining a lean workforce relative to its revenue generation capabilities.
Financial Health
The company reported a revenue of $1.10B and a net income of $186.50M for the trailing twelve months, while generating an EBITDA of $364.98M. The substantial gap between the $1.10B revenue and the $186.50M net income reveals a cost structure where approximately 16.9% of sales translate to profit, with the remaining portion absorbed by operating expenses, taxes, and interest costs. Prestige Consumer Healthcare Inc. produced free cash flow of $207.17M, which signifies strong financial flexibility allowing the firm to service debt, fund operations, or pursue strategic acquisitions without relying heavily on external financing. The company's profitability is supported by a gross margin of 57.0%, an operating margin of 29.1%, and a profit margin of 16.9%, indicating efficient production, effective cost control, and a robust bottom-line performance relative to total sales. Regarding liquidity and leverage, the firm holds $62.37M in cash against $1.08B in debt, resulting in a debt-to-equity ratio of 58.99, which characterizes a leveraged balance sheet where debt obligations exceed equity capital. Despite the high leverage, the current ratio stands at 3.11, indicating a highly conservative short-term liquidity position where current assets significantly exceed current liabilities. Management effectiveness is further highlighted by a return on equity of 10.3% and a return on assets of 6.1%, metrics that demonstrate the ability to generate returns on invested capital and utilize the asset base efficiently to produce earnings.
Valuation Assessment
The stock trades with a P/E ratio (TTM) of 15.85 and a forward P/E of 12.53, suggesting that the market expects earnings to grow in the future as the forward multiple is notably lower than the trailing multiple. The price-to-book ratio is 1.55, indicating that the market values the company at a 55% premium over its net asset book value, reflecting confidence in the brand equity and intangible assets beyond tangible holdings. Alternative valuation metrics include a price-to-sales ratio of 2.62 and an EV/EBITDA of 10.57, which suggest the company is valued at a moderate premium relative to its sales and earnings power before interest, taxes, depreciation, and amortization. The 52-week high for the stock is $89.37 and the 52-week low is $57.25, providing a context for the current trading range. Given the forward P/E of 12.53 versus the trailing P/E of 15.85, the valuation compression implies expectations of improved earnings visibility or a re-rating of the stock price relative to its historical trading bands. The beta of 0.40 indicates that the stock exhibits low volatility relative to the broader market, moving less than half as much as the overall market index during periods of fluctuation.
Growth & Income
Prestige Consumer Healthcare Inc. experienced a revenue growth (YoY) of -2.4% and an earnings growth (YoY) of -20.5% during the reported period. The disparity between the revenue decline and the more severe earnings contraction implies that earnings are growing significantly slower than revenue, or in this case, declining at a faster rate due to higher fixed cost pressures or margin compression during the downturn. As the company does not currently pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it operates as a non-dividend payer that reinvests its earnings into growth initiatives rather than distributing cash to shareholders. The overall growth and income profile reflects a mature asset in a cyclical industry where recent performance has been challenged by negative year-over-year trends in both top-line revenue and bottom-line profitability.